肝细胞癌肝移植转化治疗进展
Progress of liver transplantation conversion for hepatocelluar carcinoma
林葳 1汤宏涛 1何坤1
作者信息
- 1. 524002 湛江,广东医科大学第一临床医学院;528404 中山市人民医院普外一科(肝胆胰脾外科)
- 折叠
摘要
目前,肝移植被认为是治疗肝细胞癌(HCC)的重要方法之一,但由于肝移植标准严格,对于超出移植标准的患者,肿瘤降期无疑是一种理想的方式,其可以将肿瘤负荷降低到移植标准之内,从而降低肿瘤复发,提高生存时间.目前已有多种治疗方案,如经导管动脉化疗栓塞(TACE)、经动脉放射栓塞(TARE)、肝动脉置管持续化疗灌注(HAIC)、靶向治疗及靶向免疫联合等,被用作HCC降期治疗,但仍存在一些问题限制了HCC肝移植转化治疗的安全性和有效性.本文基于已发表的文献,对目前HCC肝移植转化治疗的现状进行简要阐述.
Abstract
Liver transplantation is currently considered as one of the most important methods for the treatment of hepatocelluar carcinoma(HCC).However,due to the strict standards of liver transplantation,many patients have exceeded the transplantation standards.For such patients,tumor downstaging is undoubtedly an ideal way,which can reduce the tumor load to the transplantation standards,thereby reducing tumor recurrence and improving survival time.There have been many kinds of descending stage treatment for HCC,such as transcatheter arterial chemoembolization(TACE),transarterial radioembolization(TARE),hepatic arterial infusion chemotherapy(HAIC),targeted therapy alone or in combination with immunotherapy.However,there are still some limits for the safety and effectiveness of liver transplantation conversion therapy for HCC.This article provides a brief introduction of the current status of liver transplantation conversion therapy for HCC based on published literature.
关键词
癌,肝细胞/肝细胞癌/转化治疗/肝移植Key words
Carcinoma,hepatocellular/Conversion therapy/Liver transplantation引用本文复制引用
出版年
2024
NETL
NSTL
万方数据